Committee for Proprietary Medicinal Products (CPMP)

@inproceedings{Nahler2009CommitteeFP,
  title={Committee for Proprietary Medicinal Products (CPMP)},
  author={Gerhard Nahler},
  year={2009}
}
Committee of the EC formed by representatives of national registration authorities; members have to assess new applications for biotechnology and other novel medicines as well as to settle disputes between member states when they disagree as to whether a product may be licensed for use in their territory; for “high-technology” products the CPMP is the chosen but not mandatory approval route; → see also multistate procedure, centralised procedure. 

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

  • British journal of pharmacology
  • 2010
VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

The use of analgesics and anti-inflammatories in an oral surgery service in Medellín , Colombia , 2013-2015

Hernández Viana, Natalia Silva Gómez, David Andrés Galvis Pareja, María Cecilia Martínez Pabón
  • 2019

A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018

[The patents game. Generic and biosimilar drugs].

  • Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial
  • 2016